Doxorubicin hydrochloride + ELRAGLUSIB
4 treatments and conditions followed through the public trial records. Not medical advice. How a status is set
Treatments and conditions
| Treatment and condition | Where it stands | Trials |
|---|---|---|
| Doxorubicin hydrochloride + ELRAGLUSIB for glioma | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Doxorubicin hydrochloride + ELRAGLUSIB for hereditary sensory and autonomic neuropathies | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Doxorubicin hydrochloride + ELRAGLUSIB for neoplasm metastasis | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Doxorubicin hydrochloride + ELRAGLUSIB for sarcoma | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |